Clinical trial

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

NCT00885612

Study summary

ClinicalTrials.gov

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

0 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

No interventions are currently published for this study in CureCurrent. View the original registry record above.

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-05-01

PhaseN/A

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

SeoulSouth Korea1 IncheonSouth Korea1 DaeguSouth Korea1 BusanSouth Korea1 SuwonSouth Korea1 GwangjuSouth Korea1 DaejeonSouth Korea1 Seongnam-siGyeonggi-do, South Korea1 Goyang-siGyeonggi-do, South Korea1 JeonjuSouth Korea1 UlsanSouth Korea1 PusanSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00885612 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.